Glaukos

Glaukos At Glaukos we are focused on pioneering new treatments for chronic eye diseases. Innovation is at the core of everything we do.

Our mission at Glaukos is to truly transform vision by pioneering novel platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to take chances and push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders and retinal diseases. ​

​Please note when clicking links in our content you will be led outside of the Glaukos page. The site you opt to connect to does not adhere to our privacy policy. You are solely responsible for your interactions on outside websites. ​

Important Safety Information​
https://www.glaukos.com/important-safety-information/

​COMMUNITY GUIDELINES: ​
Glaukos welcomes interactions and will respond to questions, comments and feedback, but responses may be delayed or limited. ​

Posts and comments contain the opinions and views of other users and Glaukos is not responsible for their accuracy or reliability. ​

​Do not post about financial, legal and regulatory issues, unsubstantiated claims about products, profanity, defamatory, offensive, discriminatory or demeaning content, threats, violence, illegal behavior, health or medical advice, false or misleading information, personal health information, or proprietary, confidential or sensitive information. ​

Follow Facebook's posting guidelines and terms of use. ​

By participating, you promise to comply with these guidelines, but we reserve the right to remove any posts that do not comply. Continuous violations may result in removal from the follower list and inability to receive news, comment or message/contact us. ​

Disclaimers: ​
Accounts followed by or following Glaukos social media channels do not indicate endorsement of the account, their products and services or content they publish. ​

Glaukos may provide links or references to other sites as part of its content, but it does not take responsibility for the content from those sites and shall not be liable for damages or injuries arising from it. These links are provided as a convenience only. ​

Glaukos reserves all rights to the channels, including the right to add, remove or modify content, discontinue the account, accept/reject followers and respond to comments. ​

Only Glaukos and its authorized users may represent Glaukos. Any other representation of Glaukos without authorization will result in legal action. ​

​Medical Side Effects/Adverse Events: ​
If you believe you have experienced any medical side effects or reactions from the Glaukos iLink cross-linking procedure or iStent portfolio of products, consult your physician or healthcare professional and report it to Glaukos by calling 1-844-528-3376, Option 1 or by contacting the FDA at 1-800-FDA-1088. ​

​Avoid sharing personal health information on social media channels, but if you do share information about any side effects, Glaukos may contact you for more information. Posts about side effects may be removed from our channels due to legal requirements. ​

Glaukos will not store or use your personal information, but if you report any adverse events or product issues, we need to store and use identifying information about you to submit it to Glaukos and/or regulatory authorities. ​

​Please be aware that Facebook also has access to information shared on our channels, refer to Facebook's Privacy Policy for more details. ​

10/09/2025

A world of firsts is here...​

Experience the beginning of the interventional glaucoma revolution at ESCRS 2025! Join Glaukos at booth E154 and Meeting Room Auditorium 11 to learn about iStent infinite®—a microinvasive, implantable device intended to reduce intraocular pressure (IOP). ​

Register today: http://bit.ly/4lEYZKs

Visit https://bit.ly/iStentInfinite_ISI for Important Safety Information.

04/09/2025

Are you ready to be part of history? Of a revolution? ​

If so, join Glaukos at ESCRS 2025 in Copenhagen for the European launch of iStent infinite®—a microinvasive, implantable device intended to reduce intraocular pressure (IOP). Stop by booth E154 to learn more about how iStent infinite® is evolving the standard of glaucoma care. We're excited to make history with you. ​

Register today: http://bit.ly/4lEYZKs

Visit https://bit.ly/iStentInfinite_ISI for Important Safety Information.

21/08/2025

Founded in 1998, Glaukos is a global ophthalmic medical technology and pharmaceutical company. We are focused on developing novel therapies for glaucoma, corneal disorders and retinal diseases. Through each innovation, we seek to transform eye care for patients living with chronic eye diseases. ​

Learn more: https://bit.ly/3DHmkLW

14/08/2025

Glaukos is committed to developing safe, high-quality products to treat chronic eye diseases. Our devices have been recognized as "best in class" because of our robust Quality Management System (QMS). Through a global training matrix, we streamline processes and ensure continuity across product development.​

Learn more in our 2024 Sustainability Report: https://bit.ly/4kvDWdL

12/08/2025

At Glaukos, we are committed to minimizing our environmental impact. That's why sustainable practices are deeply integrated into our standard operating procedures. Recently, we secured a new manufacturing site in Alabama to expand production capacity and reduce environmental risk in the event of a natural disaster in our other plants. ​

Learn more in our 2024 Sustainability Report: https://bit.ly/4kvDWdL

07/08/2025

Have you assessed your Interventional Glaucoma (IG) approaches?​

In episode 1 of The Interventional Glaucoma Project, Mark Gallardo, MD, shares how a practice assessment helped him to see gaps in his treatment approaches. Now, with an IG mindset and practice data, Dr. Gallardo, goes beyond just managing IOP to treat his glaucoma patients. ​

Watch the full episode to learn more: https://bit.ly/4lawq85

05/08/2025

As a rapidly growing company, Glaukos is dedicated to fostering a positive workplace culture that attracts top talent. Through programs like our military career events, we are promoting an exceptional, equitable workforce. ​

Our diverse team enjoys a range of benefits, including mental health support, flexible time off, student loan repayments, and more. We also host ongoing leadership development programs open to all employees. ​

Learn more in our 2024 Sustainability Report: https://bit.ly/4kvDWdL

31/07/2025

Our five key therapy platforms are designed to disrupt traditional paradigms and generate a robust cadence of new products. These platforms embody ambitious, big ideas aimed at addressing underserved eye diseases. ​

Learn more: https://bit.ly/42aANrS

29/07/2025

Join us July 30th at 4:30pm ET for a live call and webcast as we share our Q2 2025 financial results.​

Register here ➡️ https://bit.ly/3INp0tw

Over coffee and candid conversation, Drs. Christine Funke, Paul Singh, Manjool Shah and Deborah G. Ristvedt share what i...
24/07/2025

Over coffee and candid conversation, Drs. Christine Funke, Paul Singh, Manjool Shah and Deborah G. Ristvedt share what interventional glaucoma (IG) really means in their practices today. From evolving surgical strategies to patient trust and procedural innovation like iDose, this roundtable hits all the high notes in modern glaucoma care.​

Pull up a chair—this is IG, unplugged. ​

Watch full video here: https://www.youtube.com/watch?v=z3hSY5hDD0g



Disclaimer: The doctors featured in this video were compensated by Glaukos for their time and participation.

Feeling stuck in the glaucoma treatment grind? You’re not alone—but change is here. Meet the trailblazers rewriting the ...
22/07/2025

Feeling stuck in the glaucoma treatment grind? You’re not alone—but change is here.

Meet the trailblazers rewriting the rules: Dr.Christine Funke, Dr. Laura Crawley and Prof. Tina Wong are leading a shift toward interventional glaucoma, a powerful new approach that’s helping patients ditch the daily drops and gain round-the-clock IOP control. From powerful patient stories to groundbreaking MIGS and procedural pharmaceutical innovations, this eye-opening documentary shows how this movement is transforming not just lives, but healthcare systems around the World. ​

Presented by Glaukos, pioneers in interventional glaucoma. Watch the full video now and see why the future of glaucoma care is already Here. ​

Watch full video here: https://www.youtube.com/watch?v=vUiEcqU3hvw



Disclaimer: The doctors featured in this video were compensated by Glaukos for their time and participation.

15/07/2025

Join us July 30 for iDose of Knowledge episode 5: Tips for Implementing iDose® TR into a Busy Clinical Practice. ​

In this webinar episode, glaucoma experts will share tips on implementing iDose® TR into your clinical workflow so you can start taking an Interventional Glaucoma (IG) approach. ​

Register here: https://bit.ly/44UFtV8

May cause increases in intraocular pressure, iritis, and dry eye. Visit https://bit.ly/iDoseTR_PI for full Prescribing Information.​ Visit https://bit.ly/iDoseISI for Important Safety Information.

Address

1 Glaukos Way
CA
92656

Alerts

Be the first to know and let us send you an email when Glaukos posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Glaukos:

  • Want your practice to be the top-listed Clinic?

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

At Glaukos we are focused on pioneering new treatments for chronic eye diseases.

Glaucoma: Learn more about your treatment options: https://www.glaukos.com/glaucoma/

Keratoconus: Learn more about your treatment options: https://www.glaukos.com/corneal-health/

Retinal Diseases: Learn more: https://www.glaukos.com/retinal-diseases